Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Martin, Miguel; Holmes, Frankie; Ejlertsen, Bent; Delaloge, Suzette; Moy, Gül; Iwata, Hiroji; von Minckwitz, Gunter; Chia, Stephen; Mansi, Janine; Barrios, Carlos; Gnant, Michael; Tomasevic, Zorica; Denduluri, Neelima; Separovic, Robert; Gokmen, Erhan; Bashford, Anna; Borrego, Manuel; Kim, Sung-Bae; Jakobsen, Erik; Ciceniene, Audrone; Inoue, Kenichi; Overkamp, Friedrich; Heijns, Joan; Armstrong, Anne; Link, John; Abraham, Anil; Bryce, Joy; Wong, Alvin; Moran, Susan; Yao, Bin; Xu, Feng; Auerbach, Alan; Buyse, Marc; Chan, Arlene

doi:10.1016/s1470-2045(17)30717-9

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Martin M., Holmes F. A. , Ejlertsen B., Delaloge S., Moy B. , Iwata H., ...More

LANCET ONCOLOGY, vol.18, no.12, pp.1688-1700, 2017 (Journal Indexed in SCI)

Publication Type: Article / Article
Volume: 18 Issue: 12
Publication Date: 2017
Doi Number: 10.1016/s1470-2045(17)30717-9
Title of Journal : LANCET ONCOLOGY
Page Numbers: pp.1688-1700

Abstract

Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings.